SC 103Alternative Names: SC103
Latest Information Update: 04 Apr 2008
At a glance
- Originator Scancell
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Glycoprotein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 05 Aug 2005 This compound is still in active development - (BIO-2005)
- 08 Sep 2003 Preclinical trials in Cancer in United Kingdom (Parenteral)